Announcements Trials
Browse Landscape

Phase

Phase 2 36Phase 1 25Phase 3 7Phase 1/2 3Phase 4 1

Status

Terminated 3Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Endocrine 1CNS 1

Conditions

Carcinoma, Medullary 2Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia 1Gliosarcoma 1Glioblastoma 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × vandetanib × Clear all
NCT00514046 2020-12-22

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
17 enrolled 25 charts
Endocrine

Multiple Endocrine Neoplasia, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT00441142 2019-03-05

Zactima

Dana-Farber Cancer Institute

Phase 1/2 Completed
119 enrolled 15 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT01661179 2016-12-05

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Sanofi

Phase 1/2 Completed
14 enrolled 7 charts

Neoplasm Metastasis, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡